Hologic, Inc. $HOLX Shares Sold by Tealwood Asset Management Inc.

Tealwood Asset Management Inc. reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 3.2% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 15,389 shares of the medical equipment provider’s stock after selling 511 shares during the quarter. Tealwood Asset Management Inc.’s holdings in Hologic were worth $1,003,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Zions Bancorporation National Association UT acquired a new position in shares of Hologic in the 1st quarter valued at $34,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Hologic in the 1st quarter valued at $42,000. Allworth Financial LP lifted its stake in shares of Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 216 shares during the period. Larson Financial Group LLC lifted its stake in shares of Hologic by 6,016.7% in the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 722 shares during the period. Finally, West Financial Advisors LLC acquired a new position in shares of Hologic in the 1st quarter valued at $50,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $67.15 on Tuesday. The firm has a 50-day simple moving average of $66.83 and a 200-day simple moving average of $62.94. The stock has a market capitalization of $14.94 billion, a price-to-earnings ratio of 27.86, a price-to-earnings-growth ratio of 2.44 and a beta of 0.57. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Activity at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.88% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on HOLX. Evercore ISI upped their price objective on shares of Hologic from $62.00 to $68.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 8th. Mizuho set a $75.00 price objective on shares of Hologic in a research report on Thursday, July 31st. Morgan Stanley upped their price objective on shares of Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 31st. Argus upped their price objective on shares of Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. Finally, Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $79.38.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.